重症监护病房的感染控制：使用德尔菲法的 SARS-CoV-2 专家共识声明

2021-11-10 国外感染病相关专家组（统称） The Lancet Infectious Diseases

在当前的 COVID-19 大流行期间，重症监护病房 (ICU) 中的医护人员和未受感染的患者有感染 SARS-CoV-2 的风险，这是由受感染的患者和医护人员传播的结果。

中文标题：

英文标题：

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method

发布机构：

国外感染病相关专家组（统称）

发布日期：

2021-11-10

简要介绍：

在当前的 COVID-19 大流行期间，重症监护病房 (ICU) 中的医护人员和未受感染的患者有感染 SARS-CoV-2 的风险，这是由受感染的患者和医护人员传播的结果。由于缺乏关于 SARS-CoV-2 传播的高质量证据，ICU 感染控制和预防的临床实践差异很大。重症监护、传染病和感染控制领域的国际专家使用 Delphi 流程就 ICU 中 SARS-CoV-2 的感染控制制定了共识声明。33 份声明中的 31 份（94%）达成共识，其中发布了 25 份临床实践声明。这些声明包括关于 ICU 设计和工程、医护人员安全、探视政策、个人防护设备、患者和程序、消毒、杀菌。对于感染 SARS-CoV-2 的医护人员的最佳复工标准或用于 SARS-CoV-2 感染患者气道管理的热敏器械可接受的消毒策略，尚未达成共识。需要精心设计的研究来评估这些实践陈述的影响并解决剩余的不确定性。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=8c9a81c002261e5d, title=重症监护病房的感染控制：使用德尔菲法的 SARS-CoV-2 专家共识声明, enTitle=Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method, guiderFrom=The Lancet Infectious Diseases, authorId=0, author=, summary=在当前的 COVID-19 大流行期间，重症监护病房 (ICU) 中的医护人员和未受感染的患者有感染 SARS-CoV-2 的风险，这是由受感染的患者和医护人员传播的结果。, cover=https://img.medsci.cn/20211112/1636706664313_5579292.jpg, journalId=0, articlesId=null, associationId=1273, associationName=国外感染病相关专家组（统称）, associationIntro=, copyright=0, guiderPublishedTime=Wed Nov 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=在当前的 COVID-19 大流行期间，重症监护病房 (ICU) 中的医护人员和未受感染的患者有感染 SARS-CoV-2 的风险，这是由受感染的患者和医护人员传播的结果。由于缺乏关于 SARS-CoV-2 传播的高质量证据，ICU 感染控制和预防的临床实践差异很大。重症监护、传染病和感染控制领域的国际专家使用 Delphi 流程就 ICU 中 SARS-CoV-2 的感染控制制定了共识声明。33 份声明中的 31 份（94%）达成共识，其中发布了 25 份临床实践声明。这些声明包括关于 ICU 设计和工程、医护人员安全、探视政策、个人防护设备、患者和程序、消毒、杀菌。对于感染 SARS-CoV-2 的医护人员的最佳复工标准或用于 SARS-CoV-2 感染患者气道管理的热敏器械可接受的消毒策略，尚未达成共识。需要精心设计的研究来评估这些实践陈述的影响并解决剩余的不确定性。, tagList=[TagDto(tagId=43667, tagName=感染控制), TagDto(tagId=117553, tagName=德尔菲法)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=38, categoryName=急重症, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=99632, guiderKeyword=Covid-19, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=10, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3784, appHits=52, showAppHits=0, pcHits=381, showPcHits=3732, likes=0, shares=4, comments=5, approvalStatus=1, publishedTime=Tue Nov 16 23:57:56 CST 2021, publishedTimeString=2021-11-10, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Sat Nov 13 11:08:57 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Fri Jan 05 03:15:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=重症监护病房的感染控制：使用德尔菲法的 SARS-CoV-2 专家共识声明.pdf)])

重症监护病房的感染控制：使用德尔菲法的 SARS-CoV-2 专家共识声明.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1186697, encodeId=2b96118669e8f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:44 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182780, encodeId=195d1182e80db, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Mon Jan 10 10:46:51 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071645, encodeId=92f210e1645db, content=感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dbe5721458, createdName=ms8000001463605486, createdTime=Fri Nov 19 09:15:15 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071588, encodeId=408410e158852, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd305637358, createdName=ms9000000252861142, createdTime=Thu Nov 18 23:55:44 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069915, encodeId=5b1010699158f, content=谢谢，很有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=wrlssy, createdTime=Sat Nov 13 17:00:54 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
2022-01-21 mispj

学习了

84 0
[GetPortalCommentsPageByObjectIdResponse(id=1186697, encodeId=2b96118669e8f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:44 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182780, encodeId=195d1182e80db, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Mon Jan 10 10:46:51 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071645, encodeId=92f210e1645db, content=感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dbe5721458, createdName=ms8000001463605486, createdTime=Fri Nov 19 09:15:15 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071588, encodeId=408410e158852, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd305637358, createdName=ms9000000252861142, createdTime=Thu Nov 18 23:55:44 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069915, encodeId=5b1010699158f, content=谢谢，很有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=wrlssy, createdTime=Sat Nov 13 17:00:54 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
2022-01-10 mispj

感谢分享

82 0
[GetPortalCommentsPageByObjectIdResponse(id=1186697, encodeId=2b96118669e8f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:44 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182780, encodeId=195d1182e80db, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Mon Jan 10 10:46:51 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071645, encodeId=92f210e1645db, content=感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dbe5721458, createdName=ms8000001463605486, createdTime=Fri Nov 19 09:15:15 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071588, encodeId=408410e158852, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd305637358, createdName=ms9000000252861142, createdTime=Thu Nov 18 23:55:44 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069915, encodeId=5b1010699158f, content=谢谢，很有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=wrlssy, createdTime=Sat Nov 13 17:00:54 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
2021-11-19 ms8000001463605486

感谢提供

92 0
[GetPortalCommentsPageByObjectIdResponse(id=1186697, encodeId=2b96118669e8f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:44 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182780, encodeId=195d1182e80db, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Mon Jan 10 10:46:51 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071645, encodeId=92f210e1645db, content=感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dbe5721458, createdName=ms8000001463605486, createdTime=Fri Nov 19 09:15:15 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071588, encodeId=408410e158852, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd305637358, createdName=ms9000000252861142, createdTime=Thu Nov 18 23:55:44 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069915, encodeId=5b1010699158f, content=谢谢，很有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=wrlssy, createdTime=Sat Nov 13 17:00:54 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
2021-11-18 ms9000000252861142

很好

86 0
[GetPortalCommentsPageByObjectIdResponse(id=1186697, encodeId=2b96118669e8f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:44 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182780, encodeId=195d1182e80db, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Mon Jan 10 10:46:51 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071645, encodeId=92f210e1645db, content=感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dbe5721458, createdName=ms8000001463605486, createdTime=Fri Nov 19 09:15:15 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071588, encodeId=408410e158852, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd305637358, createdName=ms9000000252861142, createdTime=Thu Nov 18 23:55:44 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069915, encodeId=5b1010699158f, content=谢谢，很有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=wrlssy, createdTime=Sat Nov 13 17:00:54 CST 2021, time=2021-11-13, status=1, ipAttribution=)]
2021-11-13 wrlssy

谢谢，很有价值

91 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

传染科指南

重症监护病房的感染控制：使用德尔菲法的 SARS-CoV-2 专家共识声明

相关指南

拓展阅读

科室

工具

服务